Capital Flow Monitor · Sponsors · CIK 1324240
OrbiMed Partners II, L.P.
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK, NY, 10022 · 212-739-6400
Pooled Investment Fund / Hedge Fund · Limited Partnership· inc. DELAWARE true
Fit score
—
Offering
—
Sold
$1.78B
% sold
—
Investors
880
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | D/A ·current | 506(b) | — | $1.78B | — | 880 | EDGAR ↗ |
| 2025-07-10 | D/A | 506(b) | — | $1.78B | — | 880 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
- OrbiMed Advisors LLC — Executive Officer / Promoter, NEW YORK, NY
2 other raises
- OrbiMed Genesis Fund, Ltd. $145.9M of —
- OrbiMed Genesis Fund, L.P. $353.3M of —
-
Sven H. Borho — Executive Officer, NEW YORK, NY
5 other raises
- OrbiMed Partners, Ltd. $2.61B of —
- OrbiMed Asia Partners VI, L.P. $534.0M of $850.0M · 62.8%
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, Ltd. $145.9M of —
- OrbiMed Genesis Fund, L.P. $353.3M of —
-
Carl L. Gordon — Executive Officer, NEW YORK, NY
3 other raises
- OrbiMed Asia Partners VI, L.P. $534.0M of $850.0M · 62.8%
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
-
W. Carter Neild — Executive Officer, NEW YORK, NY
3 other raises
- OrbiMed Asia Partners VI, L.P. $534.0M of $850.0M · 62.8%
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
-
Geoffrey C. Hsu — Executive Officer, NEW YORK, NY
2 other raises
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
-
C. Scotland Stevens — Executive Officer, New York, NY
2 other raises
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
-
David Bonita — Executive Officer, New York, NY
6 other raises
- PFARADIGM Health, Inc. $31.1M of $56.1M · 55.4%
- Alpfa Medical, Inc. $80.3M of $100.3M · 80.1%
- Thrombolex, Inc. $32.8M of $51.1M · 64.1%
- Treeline Biosciences, Inc. $200.1M of $250.0M · 80.0%
- Ikena Oncology, Inc. $0 of $75.0M · 0.0%
- Adela, Inc. $25.4M of $27.0M · 94.2%
-
Matthew S. Rizzo — Executive Officer, New York, NY
2 other raises
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
-
Peter A. Thompson — Executive Officer, New York, NY
3 other raises
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
- RECODE THERAPEUTICS, INC. $29.4M of $29.4M · 100.0%
-
Mona Ashiya — Executive Officer, New York, NY
2 other raises
- OrbiMed Private Investments X, LP $1.67B of $1.75B · 95.4%
- OrbiMed Genesis Fund, L.P. $353.3M of —
Placement agents
- Far Hills Group, Llc · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.